Alphatec (NASDAQ:ATEC) Announces Earnings Results, Beats Expectations By $0.02 EPS

Alphatec (NASDAQ:ATEC) issued its quarterly earnings data on Tuesday. The medical technology company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.02, FiscalAI reports. The business had revenue of $212.93 million during the quarter, compared to the consensus estimate of $212.67 million. The company’s revenue for the quarter was up 20.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.23) EPS.

Here are the key takeaways from Alphatec’s conference call:

• Q4 revenue of $213 million (up 20% YoY) with surgical revenue +21%, Q4 Adjusted EBITDA of $33 million and $8 million of free cash flow; full-year revenue was $764 million (up 25%) with Adjusted EBITDA of $93 million (12% margin).
• Management raised full-year 2026 targets to approximately $890 million revenue (17% growth) and $134 million Adjusted EBITDA (15% margin), and expects at least $20 million of free cash flow.
• Executives highlighted a differentiated, integrated procedural ecosystem—EOS / EOS Insight imaging, SafeOp neuromonitoring, upcoming Valence navigation/robotics, 3D‑printed implants and a Theradaptive BMP partnership—which management says is driving surgeon adoption and expanding addressable markets.
• Financial leverage is improving—non‑GAAP gross margin ~70%, SG&A leverage and operating discipline produced meaningful margin expansion and ~41% full‑year drop‑through, enabling the company to self‑fund instrument and inventory investments.
• Management warned that growing deformity volumes and EOS adoption have shifted seasonality (stronger Q2/Q3), which compressed the typical Q4 sequential lift and could complicate short‑term quarter‑to‑quarter comparisons.

Alphatec Stock Up 5.9%

Shares of Alphatec stock traded up $0.77 during trading on Tuesday, reaching $13.93. The stock had a trading volume of 6,088,356 shares, compared to its average volume of 3,486,857. The company has a current ratio of 1.99, a quick ratio of 1.24 and a debt-to-equity ratio of 43.02. The company has a market capitalization of $2.07 billion, a price-to-earnings ratio of -13.39 and a beta of 1.01. Alphatec has a 52 week low of $8.81 and a 52 week high of $23.29. The stock has a fifty day moving average price of $17.09 and a two-hundred day moving average price of $17.15.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Wall Street Zen raised Alphatec from a “hold” rating to a “buy” rating in a research note on Saturday, January 31st. Canaccord Genuity Group upped their target price on shares of Alphatec from $20.00 to $25.00 and gave the company a “buy” rating in a research report on Friday, October 31st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Alphatec in a research note on Monday, December 29th. Piper Sandler reissued an “overweight” rating and set a $25.00 price target (up from $20.00) on shares of Alphatec in a research note on Friday, October 31st. Finally, TD Cowen restated a “buy” rating on shares of Alphatec in a report on Tuesday, January 27th. Ten investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Alphatec has an average rating of “Moderate Buy” and an average price target of $22.82.

Insiders Place Their Bets

In other Alphatec news, CEO Patrick Miles sold 100,000 shares of the business’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $21.01, for a total value of $2,101,000.00. Following the sale, the chief executive officer owned 5,135,398 shares in the company, valued at approximately $107,894,711.98. The trade was a 1.91% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director David R. Pelizzon sold 250,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $19.66, for a total transaction of $4,915,000.00. Following the transaction, the director directly owned 10,395,045 shares of the company’s stock, valued at $204,366,584.70. This represents a 2.35% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 1,436,125 shares of company stock worth $29,385,878 in the last 90 days. Company insiders own 22.80% of the company’s stock.

Institutional Investors Weigh In On Alphatec

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ATEC. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Alphatec by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 74,005 shares of the medical technology company’s stock worth $750,000 after buying an additional 3,196 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in Alphatec during the first quarter worth about $257,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Alphatec by 18.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 265,907 shares of the medical technology company’s stock valued at $2,696,000 after purchasing an additional 41,264 shares during the last quarter. Quantbot Technologies LP bought a new position in Alphatec in the second quarter valued at approximately $242,000. Finally, Invesco Ltd. grew its stake in Alphatec by 455.0% in the second quarter. Invesco Ltd. now owns 282,212 shares of the medical technology company’s stock valued at $3,133,000 after purchasing an additional 231,367 shares in the last quarter. 66.35% of the stock is currently owned by institutional investors and hedge funds.

About Alphatec

Alphatec Holdings, Inc (NASDAQ: ATEC) is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company’s portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec’s flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.

Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.